Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia

- THN391 was found to be safe and well-tolerated -
- THN391 demonstrated a prolonged half-life and dose proportional Cmax levels -
- The data will be presented October 25-27th at CTAD 2023 -

SACRAMENTO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced interim results from the Phase 1 trial of its lead candidate, THN391, for the treatment of dementia. The data will be detailed in a poster presentation at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference taking place from October 25-27, 2023, in Boston, MA.

Vascular dysfunction is a key driver in many neurodegenerative diseases, with fibrin playing a major role. Fibrin is a protein that is essential for blood clotting, but factors such as aging, vascular and rheumatological diseases and genetic risks, have shown fibrin to also cause chronic neuroinflammation and innate immune activation, resulting in severe retinal and neurological diseases, including Alzheimer's. THN391 is a potential first-in-class, therapeutic, monoclonal antibody that is designed to target the inflammatory properties of fibrin without disrupting coagulation and protective innate immunity.

The Phase 1 trial evaluating THN391 consists of single ascending dose (SAD) and multiple ascending dose (MAD) portions, which are designed to study the safety and tolerability of THN391 in healthy subjects, as well ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner
Related Press Releases
Happy Chinese New Year Tour Helped Ringing in the Lunar New Year with Seven Events in the United States to Showcase Chinese Craftsmanship and Art Forms

Happy Chinese New Year Tour Helped Ringing in the Lunar New...

Faceswap AI Online Tool: Anakin AI Unleash the Digital Creativity for Everyone

Faceswap AI Online Tool: Anakin AI Unleash the Digital Creat...

Lana Evanova's Impressionistic Acrylic Paintings Enchant the Art Community at Arte Fiera 2024

Lana Evanova's Impressionistic Acrylic Paintings Enchant the...

VPTrade.com Expands Reach: Innovative Trading Platform Now in Latin America and Asia

VPTrade.com Expands Reach: Innovative Trading Platform Now i...

ToyHub247.com: A New Destination for Online Toy Shopping

ToyHub247.com: A New Destination for Online Toy Shopping

SASSA Status Check launched an updated tool for grant beneficiaries

SASSA Status Check launched an updated tool for grant benefi...

Embark on a New Era of Travel and Web3-Related Ecosystem with XINTEL – The Gateway to Unprecedented SocialFi

Embark on a New Era of Travel and Web3-Related Ecosystem wit...

Real Street Capital Announces Regulation A+ Offering to Raise $25 Million for REAL STREET BUILD-TO-RENT FUND I, LLC.

Real Street Capital Announces Regulation A+ Offering to Rais...

Announcing the Launch of Kosa Salon SF’s New Website: A New Luxury Hair Salon in San Francisco

Announcing the Launch of Kosa Salon SF’s New Website: A New...